Antitumor activity of new chemical compounds in triple negative mammary adenocarcinoma models

MARTINEZ-AMEZAGA, MAITENA; CORNIER, PATRICIA G.; BOGGIÁN, DORA B.; SCHAROVSKY, OLGA G.; GIOLITO, MARÍA V.; TRAFICANTE, CARLA I.; MATA, ERNESTO G.; GIÚDICE, ANTONELA DEL; ROZADOS, VIVIANA R.; CAMACHO, CRISTIAN M.; GIORDANO, ROCÍO A.; DELPICCOLO, CARINA M.L.; MAINETTI, LEANDRO E.; RICO, MARÍA J.

Future Science OA

Future Medicine Ltd.

Año: 2020 vol. 6

Aim: According to the need for the development of new anticancer agents, we have synthetized novel bioactive compounds and aimed to determine their antitumor action. Materials & methods: We describe in vitro studies evaluating the effect of 35 novel chemical compounds on two triple negative murine mammary adenocarcinoma tumors. Results & conclusion: Three compounds were selected because of their high antitumor activity and their low toxicity to normal cells. Their effect on tumor cells apoptosis, clonogenicity and migratory capacity, were determined. We found that the selected compounds showed inhibition of viability and clonogenic capacity, and promotion of apoptosis. They also decreased the migratory capacity of tumor cells. The results obtained suggest the likelihood of their future use as antitumor and/or antimetastatic agents. Lay abstract In spite of the important progress achieved in cancer therapeutics, the percentage of people dying because of cancer is still high. Hence, we need to develop new, effective and nontoxic anticancer agents. We synthetized novel compounds and tested their antitumor effect and toxicity, in order to choose those that are effective and do not affect normal cells and therefore, are suitable for human cancer therapies. We selected three out of 35 compounds that show high antitumor action and low toxicity. Also, we studied the mechanisms by which that effect was achieved. Our next goal is to develop experiments with animals in order to have preclinical data that, hopefully, will lead to the clinical use of one or more of the selected compounds.